No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

TitleNo evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.
Publication TypeJournal Article
Year of Publication2010
AuthorsGandhi RT, Bosch RJ, Aga E, Albrecht M, Demeter LM, Dykes C, Bastow B, Para M, Lai J, Siliciano RF, Siliciano JD, Eron JJ
Corporate AuthorsAIDS Clinical Trials Group A5173 Team
JournalJ Infect Dis
Volume201
Issue2
Pagination293-6
Date Published2010 Jan 15
ISSN1537-6613
KeywordsAdult, Antiviral Agents, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes, Drug Therapy, Combination, Female, HIV Envelope Protein gp41, HIV Infections, HIV-1, Humans, Male, Peptide Fragments, Viral Load, Virus Latency
Abstract

Human immunodeficiency virus type 1 (HIV-1) persists in a latent reservoir of infected resting memory CD4 cells in patients receiving antiretroviral therapy. We assessed whether multitarget therapy with enfuvirtide, 2 reverse-transcriptase inhibitors, and a ritonavir-boosted protease inhibitor leads to decay of this reservoir. Nineteen treatment-naive patients initiated this regimen; 9 experienced virologic suppression and continued enfuvirtide-containing therapy for at least 48 weeks. In enfuvirtide-treated patients with virological suppression, there was no decay of the latent reservoir (95% confidence interval for half-life, 11 months to infinity). The stability of the latent reservoir despite intensive therapy suggests that new strategies are needed to eradicate HIV-1 from this reservoir. (ClinicalTrials.gov identifier: NCT00051831 .).

DOI10.1086/649569
Alternate JournalJ. Infect. Dis.
PubMed ID20001856
PubMed Central IDPMC2887684
Grant ListM01 RR000046 / RR / NCRR NIH HHS / United States
M01 RR000046-48 / RR / NCRR NIH HHS / United States
P20 RR011126-049001 / RR / NCRR NIH HHS / United States
P30 AI050410 / AI / NIAID NIH HHS / United States
P30 AI054907 / AI / NIAID NIH HHS / United States
P30 AI054907-01 / AI / NIAID NIH HHS / United States
P30 AI078498 / AI / NIAID NIH HHS / United States
P30 AI078498-01 / AI / NIAID NIH HHS / United States
R01 AI066992 / AI / NIAID NIH HHS / United States
R01 AI066992-05 / AI / NIAID NIH HHS / United States
U01 AI027665-13 / AI / NIAID NIH HHS / United States
U01 AI038855 / AI / NIAID NIH HHS / United States
U01 AI038855-05 / AI / NIAID NIH HHS / United States
U01 AI038858 / AI / NIAID NIH HHS / United States
U01 AI038858-06 / AI / NIAID NIH HHS / United States
U01 AI068634 / AI / NIAID NIH HHS / United States
U01 AI068634-04 / AI / NIAID NIH HHS / United States
U01 AI068636 / AI / NIAID NIH HHS / United States
U01 AI068636-04 / AI / NIAID NIH HHS / United States
U01 AI069415-03 / AI / NIAID NIH HHS / United States
U01 AI069423 / AI / NIAID NIH HHS / United States
U01 AI069423-03 / AI / NIAID NIH HHS / United States
U01 AI069450 / AI / NIAID NIH HHS / United States
U01 AI069450-03 / AI / NIAID NIH HHS / United States
U01 AI069472 / AI / NIAID NIH HHS / United States
U01 AI069472-03 / AI / NIAID NIH HHS / United States